"Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management

Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Human vaccines & immunotherapeutics Jg. 18; H. 3; S. 1889449
Hauptverfasser:	Sollena, Pietro, Cappilli, Simone, Federico, Francesco, Schinzari, Giovanni, Tortora, Giampaolo, Peris, Ketty
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Taylor & Francis 31.05.2022 Taylor & Francis Group
Schlagworte:	Advanced melanoma Antibodies, Monoclonal - adverse effects Antineoplastic Agents, Immunological - adverse effects CTLA-4 Antigen - antagonists & inhibitors CTLA-4 inhibitors cutaneous adverse events Exanthema - chemically induced Humans immune checkpoint inhibitors Immunotherapy - adverse effects Melanoma - drug therapy Melanoma – Mini-Review PD-1 inhibitors skin rash skin rash cutaneous adverse events PD-1 inhibitors immune checkpoint inhibitors Advanced melanoma CTLA-4 inhibitors
ISSN:	2164-5515, 2164-554X, 2164-554X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated protein 4, anti-programmed cell death protein 1 and its ligand inhibitors have been approved for advanced melanoma among other solid cancers. Although immunotherapy demonstrated a good safety profile, a new spectrum of multisystemic immune-related adverse events has been recently reported due to their use. Cutaneous reactions represent one of the leading adverse events, often reported in literature as "skin rash", and rarely further characterized in distinct dermatologic entities. Herein we describe the distinctive cutaneous rashes occurring during immunotherapies for advanced melanoma, discussing implications in the treatment management.
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2164-5515 2164-554X 2164-554X
DOI:	10.1080/21645515.2021.1889449